

**UNIVERSITI TEKNOLOGI MARA**

**A STUDY ON NUCLEATION  
KINETICS OF CARBAMAZEPINE-  
FUMARIC ACID FORM B  
COCRYSTAL**

**MOHAMAD ZULHELMI BIN MOHD ZAWAWI**

Thesis submitted in fulfillment of the requirements  
needed for the award of **Bachelor of Engineering (Hons.)**  
**Chemical and Process**

**Faculty of Chemical Engineering**

July 2017

## ABSTRACT

Cocrystallization is a common technique selected by many researchers in purpose to enhance pharmaceutical drugs properties and nucleation kinetics is one of the important parameter to perform cocrystallization. However, the nucleation kinetics for carbamazepine-fumaric acid form B cocrystal has not been studied. The purpose of this experiment is to study on nucleation kinetics of CBZ-FUM acid form B by using Nývlt's approach. In this study, carbamazepine (CBZ) was selected as API and fumaric acid (FUM) was used as coformer in order to produce CBZ-FUM form B cocrystal. To ensure form B was produced, stoichiometric ratio of 1:2 of CBZ to FUM was used in this study. Metastable zone width (MSZW) was studied by manipulating the solution concentration in range from 0.0467 g/mL to 0.0512 g/mL. Besides that, the effect of cooling rate on MSZW also was studied by varying the cooling rate (0.10, 0.25, 0.50, and 0.75 °C/min). Based on results obtained, the MSZW was increased as cooling rate increases but concentration has insignificant effect on MSZW. The nucleation rate obtained was in range of 0.1325 to 1.3052. Cocrystal also undergoes characterization process by using FTIR microscopy and optical microscope. Based on FTIR results, cocrystal peaks was formed at above and below of pure component peaks. For XRPD result, it shows that CBZ-FUM form B cocrystal has developed 5 new peaks in between 6.6° and 34° 20. Meanwhile, peaks on DSC result between range 185 °C and 186.5 °C were proved the formation of form B polymorph. Lastly, CBZ-FUM form B cocrystal that formed has needle-like morphology.

## **ACKNOWLEDGEMENT**

First of all, thank you Allah S.W.T for giving me the strength to finish up this research project thesis. Without Your Willingness, I would not be able to complete this project. I also would like to thank my respected supervisor, Dr. Nornizar Anuar and other lecturers, Dr. Siti Nurul 'Ain Yusop and Sir Muhamad Fitri Othman who have given me their constant encouragement, constructive advices and continuous guidance during this research project. Besides that, I would like to thank them for being patient in monitoring my progress in this project.

Furthermore, not to forget their contributions in finance support from corresponding grants to achieve the research targets. My parents are my biggest supporters and I will not be here if not for their prayers and patience. The appreciation and special thanks also goes to the cooperative postgraduate students, Umi Rafiah, Nik Salwani and Vanessa for their guidance in helping me carrying out the experiments and finishing the report. Last but not least, my many thanks to lab technicians whom tolerance levels are beyond expectation.

## TABLE OF CONTENTS

|  |      |
|--|------|
| <b>AUTHOR'S DECLARATION</b>                                  | i    |
| <b>ABSTRACT</b>  | iii  |
| <b>ACKNOWLEDGEMENT</b>                                       | iv   |
| <b>TABLE OF CONTENTS</b>                                     | v    |
| <b>LIST OF FIGURES</b>                                       | viii |
| <b>LIST OF TABLES</b>  | x    |
| <b>LIST OF SYMBOLS</b>                                       | xi   |
| <b>LIST OF ABBREVIATIONS</b>                                 | xii  |
| <br>   |      |
| <b>CHAPTER ONE: INTRODUCTION</b>                             | 1    |
| 1.1 Background Of Study                                      | 1    |
| 1.2 Problem Statement  | 3    |
| 1.3 Research Objectives                                      | 4    |
| 1.4 Scope And Limitations Of Study                           | 4    |
| 1.5 Outline Of Thesis  | 5    |
| <br>   |      |
| <b>CHAPTER TWO: LITERATURE REVIEW</b>                        | 6    |
| 2.1 Pharmaceutical Active Ingredients (APIs)                 | 6    |
| 2.1.1 Properties of Active Pharmaceutical Ingredients (APIs) | 6    |
| 2.2 Cocrystallization  | 8    |
| 2.3 Definition Of Cocrystal                                  | 9    |
| 2.3.1 Pharmaceutical Cocrystal Design Strategies             | 10   |
| 2.3.2 Supramolecular Synthon                                 | 11   |
| 2.3.3 Physicochemical Properties of Cocrystal                | 12   |
| 2.4 Carbamazepine  | 13   |
| 2.4.1 Carbamazepine Cocrystal Studies                        | 16   |
| 2.5 Coformer   | 17   |

# CHAPTER ONE

## INTRODUCTION

### 1.1 BACKGROUND OF STUDY

Pharmaceutical drug is use for the purpose of preventing, curing and treating different types of diseases and illness. In pharmaceutical industry, these drugs are called as medicines. This pharmaceutical drug is able to relieve pain and help to control the severity of mental and physical diseases. Examples of diseases and illness that can be treat or control by using pharmaceutical drugs is cough and cold, diabetes, cancer, headache, heart attack, hypertension, epilepsy, and many other diseases.

Carbamazepine is one of the examples of pharmaceutical drug or medicine. Carbamazepine is an anticonvulsant used to treat seizures and nerve pain such as diabetic neuropathy and bipolar disorder. Anticonvulsant is a drug substance that prevents or reduces the severity and seizure frequency of epilepsy disease. This anticonvulsant has different mode of action when it acts on different receptors in the brain.

Pharmaceutical drug is classified into several classes based on its pharmaceutical properties. For example, carbamazepine is classified as a class III pharmaceutical agent. This type of class has unique and different characteristic compared to other classes. Class III product has low solubility but high permeability in the biopharmaceutical system (Limwikrant *et al*, 2012).

Poor solubility of pharmaceutical product is a common problem faced by pharmaceutical manufacturers during handling this drug. Drugs that have poor solubility properties will lead to slow dissolution in biological system, insufficient and lack of efficiency of the drug performance (Rahim *et al*, 2015). Besides that, solubility of drug is a main key for pharmaceutical drug performance. According to Rahim *et al*, low biosorption properties, toxicity and lack of efficacy are the major reason of only less than 1% of active pharmaceutical ingredient is produce into the market place.